Several important new papers on aspergillosis, diagnosis, and antifungal therapy were published this week. These include updated UK guidance, new antifungal drug targets, and insights into diagnosing invasive disease in ICU settings.

---

1. British Society for Medical Mycology (BSMM) Best Practice Guidance

First author: Dr Rebecca Gorton
Institution: British Society for Medical Mycology (UK)
Published: Nov 2025
Focus: Diagnosis + antifungal stewardship + clinical scenarios

Summary

This newly updated best-practice article explains how clinicians should:

• combine CT scans, IgG/IgE, PCR, and galactomannan

• choose antifungals appropriately

• avoid misdiagnosis

• apply practical recommendations to real-world cases

It is one of the most up-to-date UK-relevant guidance documents.

Why this matters for patients

Better diagnosis → faster correct treatment → fewer unnecessary antifungals.

---

2. Diagnostic Algorithms for Invasive Aspergillosis in ICU Patients

First author: Dr Anne-Sophie Hartmann
Institution: University Hospital Freiburg, Germany
Published: Jun 2025
Focus: ICU diagnosis & emerging risk groups

Summary

This study shows that invasive aspergillosis is increasingly found in ICU patients, including those who do not have classic risk factors.
It tests new diagnostic “pathways” combining imaging and multiple laboratory markers.

Why this matters for patients

Improves early recognition of life-threatening fungal infections in critical illness.

---

3. Advances in Antifungal Drug Discovery (FK1 and new targets)

First author: Dr Jonathan Miles
Institution: University of Cambridge, UK
Published: Aug 2025
Focus: New drug targets & antifungal discovery

Summary

This review outlines progress in antifungal development, including:

• Fungal Kinase 1 (FK1) as a new therapeutic target

• new chemical classes

• failings of older antifungals

• the need for next-generation medicines

Why this matters for patients

Future antifungals may be more effective, safer, and active against resistant Aspergillus.

---

4. British Thoracic Society (BTS) Clinical Statement on Aspergillus Lung Disease

Lead author (Chair): Dr Elizabeth Sapey
Institution: University of Birmingham / British Thoracic Society
Published: May 2025
Focus: Chronic Aspergillus disease (CPA, ABPA, SAFS, Aspergillus bronchitis)

Summary

This statement sets out national guidance to improve diagnosis and management of chronic Aspergillus-related lung disease.
It supports earlier testing, consistent management, and clearer referral pathways.

Why this matters for patients

• Better recognition of CPA and ABPA

• Fairer access to specialist care

• More consistent treatment across the UK

---

5. New Antifungal Drug Classes in Development (Rezafungin, Ibrexafungerp, Olorofim)

First author: Prof David Denning
Institution: University of Manchester / NAC
Published: Sep 2025
Focus: Emerging antifungal drugs

Summary

This review discusses the latest antifungal medicines in the pipeline:

• Rezafungin – long-acting IV drug

• Ibrexafungerp – new oral class

• Olorofim – strong activity against resistant Aspergillus

It explains mechanisms of action, clinical trial progress, and potential future roles.

Why this matters for patients

New drugs are on the way to treat resistant and difficult Aspergillus infections.

---

📘 Summary Table (with authors & institutions)

---

💬 Overall Takeaway for Patients

Recent publications show strong progress:

• Diagnosis is improving, especially in ICU and chronic disease clinics.

• New antifungals are progressing, including drugs designed specifically to address resistance.

• UK-specific guidance is strengthening, helping ensure more consistent, high-quality treatment for ABPA, CPA, SAFS, and Aspergillus bronchitis.

This is a period of rapid advancement in aspergillosis care, and the findings highlighted here directly support better outcomes for patients.

Path: Start » Research » ⭐ Recent Aspergillosis Research & Guideline Updates (Week 47)